LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).
Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered.

IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).
Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered.

Lung Transplant; Complications

Immunosuppression regimen with Tacrolimus Extended Release as the backbone.

Tacrolimus Extended Release Oral Tablet [Envarsus]

Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.

Tacrolimus

Standard immunosuppression of the anti-proliferative class.

Mycophenolate Mofetil Hydrochloride

Standard immunosuppression (corticosteroid class).

Prednisone

Azathioprine

Vanderbilt University Medical Center

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant Recipients

Composite of mortality, allograft failure, potential drug induced liver injury, supra-therapeutic trough levels (>20 ng/mL), sub-therapeutic trough levels (<5 ng/mL), seizures, encephalopathy, thrombotic microangiopathy and serious hyperkalemia associated with use of LCP-tacrolimus, compared to matched historical controls administered IR-tacrolimus.

Median change in eGFR from study start to 9 months post-transplantation with patients administered LCP-tacrolimus compared to IR-tacrolimus.

Quality of life related to headache frequency and severity using the Headache Impact Tool (HIT-6).

Quality of life related to tremor as measured by the QUEST tool.

Incidence of acute cellular rejection (>= A1) or lymphocytic bronchiolitis (>= B1R)

Incidence of de novo donor-specific anti-HLA antibodies (MFI > 1500) within the first 9 months post-transplant.

bronchiolitis obliterans/էպիլեպտիկ նոպա

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Բժշկական դեղաբույսերի ամենալավ տվյալների շտեմարանը, որին աջակցում է գիտությունը